5.84
+0.11(+1.92%)
Currency In USD
| Previous Close | 5.73 |
| Open | 5.7 |
| Day High | 5.86 |
| Day Low | 5.66 |
| 52-Week High | 12.65 |
| 52-Week Low | 5.51 |
| Volume | 1.22M |
| Average Volume | 5.1M |
| Market Cap | 1.8B |
| PE | -64.89 |
| EPS | -0.09 |
| Moving Average 50 Days | 6.29 |
| Moving Average 200 Days | 8.88 |
| Change | 0.11 |
If you invested $1000 in Amicus Therapeutics, Inc. (FOLD) 10 years ago, it would be worth $416.55 as of July 01, 2025 at a share price of $5.84. Whereas If you bought $1000 worth of Amicus Therapeutics, Inc. (FOLD) shares 5 years ago, it would be worth $375.56 as of July 01, 2025 at a share price of $5.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
GlobeNewswire Inc.
Jun 25, 2025 11:00 AM GMT
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD)PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Japa
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
GlobeNewswire Inc.
Jun 03, 2025 11:00 AM GMT
PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cip
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
GlobeNewswire Inc.
May 30, 2025 11:00 AM GMT
PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies Global Healthcare Conference 20